Semaglutide

Long-acting GLP-1 receptor agonist

Ficha técnicaLZH-001

Código: GLP-1 RA
Fórmula: C187H291N45O59
Masa molecular: 4113.6 Da
Semivida: ~165 h (≈ 7 days)
Vía de investigación: Subcutaneous (research)
Dianas moleculares: GLP-1R (Gs-coupled)
Descubrimiento / divulgación: Disclosed 2012, Novo Nordisk
Pureza objetivo: ≥ 98%
Almacenamiento recomendado: −20 °C, protegido de la luz. De 2 a 8 °C tras la reconstitución.

Sinónimos

NN9535, Ozempic, Wegovy, Rybelsus

Aspecto

White to off-white lyophilized powder

Solubilidad

Soluble in pH 7.4 aqueous buffer; sparingly soluble in cold water

Secuencia

HAibEGTFTSDVSSYLEGQAAK(γE-2xOEG-C18 diacid)EFIAWLVRGRG

Analistas revisando el cromatograma de HPLC del lote actual — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Técnico supervisando un reactor de acero inoxidable durante el escalado — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Descripción general

Semaglutide is a long-acting GLP-1 receptor agonist built from a 31 amino acid modified peptide sequence designed for once-weekly dosing. Its structure derives from native GLP-1, with a fatty acid side chain attached at Lys26 to extend half-life.

Farmacología y mecanismo

Activates the GLP-1 receptor, promoting glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying and acting on hypothalamic appetite centers. The effect is glucose-dependent, so hypoglycemia risk is low.

Áreas de investigación

R.01

Long-acting GLP-1 receptor agonist

Widely studied in type 2 diabetes metabolic control, obesity management and cardiovascular risk reduction. Active research directions include neurodegenerative disease, NAFLD and addictive behavior modulation.